Abstract
Background The extent of infection by coronavirus disease 2019 has not been well known. In this study we aimed to determine seropositivity of COVID-19 virus infection in population of a highly affected area in north of Iran.
Methods In a population-based cluster random sampling design through phone call invitation, a total of 196 household including 551 subjects agreed to participate in this study. Each participant were taken 50ml blood sample at health care center. Rapid test kits were used to detect antibody against COVID-19. Crude, population-weight adjusted and test performance adjusted prevalence of antibody seropositivity to SARS-CoV-2 were reported.
Results The prevalence of antibody seropositivity was 22% (95%CI: 19-26%). The population weight adjusted estimate was 21% (95%CI: 14-29%) and test performance adjusted prevalence was 33% (95%CI: 28-39%). Based on these estimates the range of infected people in this province would be between 518000 and 777000.
Conclusion The population seropositivity prevalence of COVID-19 virus infection indicated that the asymptomatic infection is much higher than the number of confirmed cases of COVID-19. This estimate can be used to better detect infection fatality rate and decide for public policy guidelines.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research has been sponsored by Iran’s Ministry of health and performed under a research grant from deputy of research at Guilan University of medical sciences. The authors are grateful to all health centers' employees and personnel for cooperating and conducting the survey as well as participants that took part in this research.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are not publicly available.
